Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
People
Thomas N. Salzmann
by Susan J. Ainsworth
December 14, 2009
| A version of this story appeared in
Volume 87, Issue 50
Thomas N. Salzmann, 60, a scientific leader at Merck & Co. whose seminal research in the field of antibiotics led to the discovery of Primaxin, died on Oct. 30.
Salzmann earned an undergraduate degree from Colgate University in 1971 and a Ph.D. in synthetic organic chemistry in 1975 from the University of Wisconsin, Madison, working in the laboratory of Barry M. Trost.
Salzmann joined Merck Research Laboratories in 1975 as a senior research chemist at its Rahway, N.J., site.
During his early years at Merck, Salzmann’s contribution to the discovery of Primaxin earned him the company’s prestigious Director’s Award in 1984.
He was promoted to lead the overall drug discovery efforts at the Rahway site in 1999, and under his leadership the drugs Cancidas for fungal infections, Emend for chemotherapy-related nausea and vomiting, and Januvia for type 2 diabetes were discovered.
In 2002, Salzmann was appointed to lead Merck’s Worldwide Preclinical Development organization, and he assumed additional responsibility for Project Management & Global Operations later that year. He retired from Merck in 2004.
He was also a founding board member of Sirtris Pharmaceuticals (now part of GlaxoSmithKline). Salzmann was a retired member of ACS, having joined in 1973.
He is survived by his wife, Susan; three children, Kate Muti, Gretel, and Matt; and four grandchildren, Madison, Jane, Owen, and Finn.
Susan J. Ainsworth writes obituaries. Obituary notices may be sent to s_ainsworth@acs.org and should include a detailed educational and professional history.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X